What Is Elvanse Used For? A UK Guide to ADHD and BED Treatment
Elvanse (lisdexamfetamine) is a once‑daily stimulant medication widely used in the UK as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD). In the UK, Elvanse is licensed for ADHD in children aged 6 years and over when methylphenidate has not worked well enough, and for adults who had ADHD symptoms in childhood. Although lisdexamfetamine is licensed for binge eating disorder (BED) in some countries (notably the US), it is not UK‑licensed for BED; any use for BED in the UK would be specialist, off‑label prescribing and is not routinely recommended by NICE.
This guide explains what Elvanse is used for in the UK, how it works, who can take it, typical dosing and titration, common side effects, and what patients and clinicians should know about BED prescribing outside the licence.
What is Elvanse (lisdexamfetamine)?
Elvanse is the UK brand name for lisdexamfetamine, a central nervous system stimulant and prodrug of dexamfetamine. As a prodrug, it is inactive until converted in the body, which gives a smoother, longer effect and lower misuse potential than immediate‑release amphetamines. Elvanse is a Class B controlled drug in the UK and must be prescribed and monitored by a specialist (usually a psychiatrist or specialist ADHD service).
In the UK, Elvanse capsules come in strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg, allowing gradual dose titration.
What is Elvanse licensed for in the UK?
ADHD in children and adolescents (6+ years)
Elvanse is indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. “Comprehensive treatment programme” means medication is combined with behavioural, educational, and parenting interventions where appropriate.
ADHD in adults
Elvanse is also indicated for ADHD in adults with pre‑existing symptoms of ADHD in childhood, following a full clinical assessment. NICE NG87 recommends lisdexamfetamine as first‑line pharmacological treatment for adults with ADHD, after baseline cardiovascular and psychiatric risk assessment.
Binge eating disorder (BED): UK position
In the US, lisdexamfetamine (Vyvanse) is licensed for moderate‑to‑severe BED in adults. In the UK, however, the product information (SmPC/EMC) and BNF confirm that Elvanse is licensed only for ADHD. There is currently no medication licensed in the UK specifically for BED. Any use of lisdexamfetamine for BED in the UK is off‑label, typically limited to specialist psychiatry or eating disorder services, and is not routinely recommended by NICE.
How Elvanse works in ADHD (and why it helps)
Lisdexamfetamine increases levels of dopamine and noradrenaline in key brain circuits involved in attention, impulse control, and executive function. In practical terms, this often translates into:
Better sustained concentration and task completion
Reduced impulsivity and restlessness
Improved working memory and organisation
Less mental “noise” and emotional reactivity
Because it is a prodrug with a long duration of action (around 13 hours on average), Elvanse usually provides once‑daily coverage across the school or work day.
Who should (and should not) take Elvanse?
Suitable candidates
Children aged 6+ with severe ADHD, or moderate ADHD that has not responded adequately to non‑pharmacological interventions and methylphenidate.adhdbrainscan+1
Adults with a confirmed ADHD diagnosis, significant impairment, and pre‑existing childhood symptoms, following specialist assessment.
Use with caution or avoid
Significant cardiovascular disease, uncontrolled hypertension, or certain heart rhythm disorders (baseline BP, pulse, and history are required).
History of psychosis, bipolar mania, or severe anxiety that could be worsened by stimulants.
Hyperthyroidism, glaucoma, or known hypersensitivity to amphetamines.
Current or recent use of monoamine oxidase inhibitors (MAOIs).
A specialist will review medical history, current medications, and risk factors before starting Elvanse.
Typical dosing and titration in the UK
Elvanse is taken once daily in the morning. Dosing is individualised and titrated to balance benefit and side effects.
Adults
Starting dose: 30 mg once each morning.
Titration: Increase by 20 mg at weekly intervals based on response and tolerability.
Maximum dose: 70 mg daily.
Children and adolescents (6+ years)
Similar stepwise titration from 30 mg, adjusted by the specialist according to weight, response, and side effects, up to a maximum of 70 mg daily.
Titration typically takes 4–12 weeks. Patients are often asked to keep a symptom and side‑effect diary to guide dose adjustments.
Common side effects and how to manage them
Most side effects are mild, dose‑dependent, and improve over the first 2–4 weeks as the body adjusts.
Very common / expected
Reduced appetite and possible weight loss
Difficulty falling asleep (especially if taken late)
Dry mouth
Headache, dizziness
Abdominal discomfort, nausea
Feeling anxious, irritable, or jittery
Faster heartbeat or mild rise in blood pressure
Management tips:
Eat a substantial breakfast before the medication kicks in; plan calorie‑dense snacks.
Take Elvanse early in the morning; avoid caffeine after midday.
Stay well hydrated; use sugar‑free gum or lozenges for dry mouth.
Report persistent insomnia, marked mood changes, or significant appetite/weight loss to your prescriber.
Serious – seek urgent medical advice
Chest pain, fainting, breathlessness, or a new irregular heartbeat
Signs of psychosis, mania, or severe aggression
Seizure
Severe allergic reaction (facial/throat swelling, breathing difficulty)
Painful, prolonged erection (priapism)
Cold, painful, or discoloured fingers/toes (peripheral vasculopathy)
New or worsening suicidal thoughts or dangerous behavioural change
Elvanse and binge eating disorder (BED) in the UK
Binge eating disorder is characterised by recurrent episodes of eating large amounts of food with a sense of loss of control, without regular compensatory behaviours (e.g., purging). In the US, lisdexamfetamine is licensed for moderate‑to‑severe BED in adults and has strong trial evidence showing reduced binge days.
In the UK:
Elvanse is licensed only for ADHD.
There is no UK‑licensed medication specifically for BED.
Any use of lisdexamfetamine for BED is off‑label, usually considered only after psychological therapies (such as CBT‑ED) have been tried, and typically managed by specialist eating disorder or psychiatric services.
Patients considering medication for BED in the UK should discuss:
Evidence‑based psychological treatments first (guided self‑help, CBT‑ED, specialist eating disorder programmes).
Whether off‑label lisdexamfetamine is appropriate given their history, cardiovascular risk, and comorbidities.
The need for careful monitoring of appetite, weight, mood, sleep, and cardiovascular parameters.
Monitoring and follow‑up
During titration and maintenance, specialists typically monitor:
Blood pressure, pulse, and weight at baseline and regularly thereafter
Sleep, appetite, and mood changes
ADHD symptom response and functional improvement (work, study, relationships)
In children, growth parameters over time
Once stable, many patients transition to shared care with their GP for repeat prescribing, with the specialist retaining oversight of dose changes and complex issues.
FAQs: What is Elvanse used for?
Is Elvanse licensed for binge eating disorder in the UK?
No. In the UK, Elvanse (lisdexamfetamine) is licensed only for ADHD. Use for BED is off‑label and not routinely recommended by NICE; it is considered only by specialists in selected cases.
How long does Elvanse take to work?
Many people notice improved focus and reduced impulsivity within hours of the first dose, but finding the optimal dose usually takes 4–12 weeks of titration.
Can I drink alcohol while taking Elvanse?
Alcohol can worsen side effects such as dizziness, anxiety, and sleep problems, and may mask how the medication is affecting you. Most clinicians advise avoiding or strictly limiting alcohol, especially during titration.
Will Elvanse help with weight loss?
Reduced appetite and some weight loss are common side effects, but Elvanse is not a weight‑loss medication. Intentional use for weight control is inappropriate and potentially dangerous.
Is Elvanse addictive?
As a Class B controlled drug, Elvanse has misuse potential, though its prodrug design lowers abuse risk compared with immediate‑release stimulants. It should be taken exactly as prescribed and stored securely.
Ready to start or transfer your ADHD treatment?
If you’re considering Elvanse for ADHD, struggling with your current medication, or looking to move your prescribing to a specialist UK service, Focus Gently offers structured assessments and specialist‑led titration pathways. For patients who already have a diagnosis and want to transfer prescribing, Focus Gently provides a dedicated ADHD prescribing transfer service.
Book your ADHD Assessment today at focusgently.com Or, if you already have a diagnosis and want to transfer prescribing, visit focusgently.com/adhd-prescribing-transfer.
